AstraZeneca Plc CEO Soriot: Would recommend bid at the right valuation - financial press cites BBC interview
- If the price that is offered reflects the full value of the company and justifies the risks that are attached to this transaction, then of course we would have to make a positive recommendation.
- The risk of new drugs being delayed by the merger could be substantial but is manageable.